Liver Fat Reduction With Retatrutide: Why the Phase 2 Data Are Significant

The Scale of the Problem

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), affects an estimated 25-30% of adults worldwide. It is the most common chronic liver disease in the world and a leading cause of liver transplants. MASLD runs from simple steatosis (fat buildup in the liver) to steatohepatitis (MASH/NASH), fibrosis, cirrhosis and hepatocellular carcinoma.

Despite this huge burden, there have been almost no drugs for MASLD. Until very recently, none were approved specifically for it, and standard care was limited to lifestyle change: losing weight through diet and exercise. That works, but it is hard to sustain at the level needed (usually >7-10% of total body weight to meaningfully reduce liver fat).

That context explains why retatrutide’s Phase 2 liver fat data have drawn so much interest.

What the Phase 2 Data Showed

The Phase 2 obesity trial included a liver fat substudy that measured liver fat using MRI-derived proton density fat fraction (MRI-PDFF), the current gold standard for measuring liver fat without a biopsy. The substudy enrolled 98 people with MASLD and at least 10% liver fat. At the highest dose (12 mg), liver fat fell by 82.4% (relative) at 24 weeks, the primary endpoint, and by 86.0% at 48 weeks (Sanyal et al., Nature Medicine, 2024).

To put this in perspective:

• Participants started with average liver fat levels in the moderate-to-severe steatosis range.
• At week 24, 79% (8 mg) and 86% (12 mg) had liver fat below 5%, the usual threshold for defining hepatic steatosis. At week 48 the figures were 89% and 93%, among fewer participants scanned.
• Liver fat fell more at higher doses, which points to an effect of the drug rather than chance.

Beyond Weight Loss: A Direct Hepatic Effect

Weight loss alone reduces liver fat. This is well established: losing about 5-7% of total body weight usually cuts liver fat by 25-30% in relative terms. GLP-1 receptor agonists like semaglutide, which produce large weight loss, have shown liver fat reductions of about 30-45%.

The roughly 82% reduction seen with retatrutide is far more than weight loss alone would predict. Even allowing for the 24.2% body weight reduction at the highest dose, the amount of liver fat cleared points to a direct effect of the drug on how the liver handles fat, beyond the indirect benefit of less body fat.

The most likely driver is retatrutide’s glucagon receptor component. Glucagon directly stimulates beta-oxidation of fatty acids in the liver, the pathway the liver uses to break down stored triglycerides for energy. This is a very different mechanism from weight loss through lower appetite. In effect, it tells the liver to clear its fat stores, rather than just cutting the supply of new fat by eating less.

Comparison to Other Approaches

To see why these data matter, compare them with other treatments:

Lifestyle intervention: The most effective lifestyle programs achieve 7-10% total body weight loss and about 30-40% liver fat reduction. Keeping it up is a major challenge.

GLP-1 receptor agonists (semaglutide): Phase 2 data in MASH showed meaningful improvement in liver tissue, with liver fat reductions of about 30-45%. In August 2025 the FDA granted semaglutide (Wegovy) accelerated approval for MASH with moderate to advanced fibrosis, based on interim results of the Phase 3 ESSENCE trial.

Tirzepatide (GIP/GLP-1 dual agonist): The SYNERGY-NASH trial showed significant improvement in liver tissue in MASH, with liver fat reductions probably driven by large weight loss. Specific liver fat measurements are starting to appear.

Resmetirom (thyroid hormone receptor beta agonist): Approved as the first treatment specifically for MASH with fibrosis, resmetirom reduces liver fat through a different, thyroid-based mechanism. Its fat reduction is meaningful but smaller than the retatrutide signal.

Bariatric surgery: Produces the largest liver fat reductions of the established treatments, bringing liver fat close to normal in many patients. Surgery carries procedural risks, though, and is not suitable for everyone.

Retatrutide’s roughly 82% liver fat reduction at 24 weeks is among the largest reported for a drug in a controlled trial, though it comes from a small substudy and cross-trial comparisons are imprecise.

Implications for MASLD Treatment

If Phase 3 confirms the Phase 2 liver fat findings, the impact on MASLD treatment could be large:

A pharmacological alternative to surgery: For patients with severe fatty liver who cannot have, or do not want, bariatric surgery, retatrutide could clear liver fat to a similar degree with a weekly injection.

Addressing the full disease spectrum: By sharply reducing liver fat, retatrutide might prevent simple steatosis from progressing to steatohepatitis and fibrosis. Whether it can reverse established fibrosis is a key question for the Phase 3 MASLD trial.

Combination potential: Glucagon-driven fat burning in the liver works differently from other MASLD therapies, so it could complement them, including resmetirom, which acts through thyroid receptor pathways. Combinations may eventually work even better.

Important Caveats

There are real limits to these data. The liver fat substudy was part of a Phase 2 trial with a fairly small sample. MRI-PDFF measures total liver fat but not inflammation or fibrosis, which are what determine how serious MASLD is. Tissue data (from liver biopsy) will be needed to confirm that lower fat means real improvement in liver disease.

The 48-week duration also leaves open how long the effect lasts, and whether liver fat stays down with continued treatment or rebounds if treatment stops.

Looking Forward

Retatrutide’s Phase 3 liver program runs separately from the TRIUMPH obesity trials. SYNERGY-Outcomes, which is recruiting, tests whether retatrutide prevents major adverse liver outcomes in adults with MASLD/MASH, with liver fat imaging among its secondary measures (see SYNERGY-Outcomes and MACELD explained). This program will show whether the Phase 2 liver fat signal holds up and, more importantly, whether it leads to real clinical benefit for the liver.

For a disease that affects a quarter of adults worldwide and has few treatments, retatrutide’s liver fat data are among the most promising drug signals so far. The Phase 2 findings do not prove clinical benefit; that needs Phase 3 confirmation. But they give a strong biological rationale and a clear path toward one of the largest unmet needs in metabolic medicine.